UTHR Quote, Financials, Valuation and Earnings

Corcept Therapeutics, Inc. has a net margin of 42.36% compared to United Therapeutics Corp.'s net margin of 9.32%. United Therapeutics Corp.'s return on equity of 19.2% beat Corcept Therapeutics, Inc.'s return on equity of 16%.

United Therapeutics Corp. has a consensus price target of $518.25, signalling upside risk potential of 0.22%. On the other hand Corcept Therapeutics, Inc. has an analysts' consensus of $127.20 which suggests that it could grow by 51.86%. Given that Corcept Therapeutics, Inc. has higher upside potential than United Therapeutics Corp., analysts believe Corcept Therapeutics, Inc. is more attractive than United Therapeutics Corp..

United Therapeutics Corp. has a beta of 0.861, which suggesting that the stock is 13.874% less volatile than S&P 500. In comparison Corcept Therapeutics, Inc. has a beta of 0.197, suggesting its less volatile than the S&P 500 by 80.287%.

United Therapeutics Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Corcept Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. United Therapeutics Corp. pays -- of its earnings as a dividend. Corcept Therapeutics, Inc. pays out -- of its earnings as a dividend.

United Therapeutics Corp. quarterly revenues are $799.5M, which are larger than Corcept Therapeutics, Inc. quarterly revenues of $207.6M. United Therapeutics Corp.'s net income of $338.7M is higher than Corcept Therapeutics, Inc.'s net income of $19.4M. Notably, United Therapeutics Corp.'s price-to-earnings ratio is 19.60x while Corcept Therapeutics, Inc.'s PE ratio is 95.70x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for United Therapeutics Corp. is 7.97x versus 13.51x for Corcept Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Gilead Sciences, Inc. has a net margin of 42.36% compared to United Therapeutics Corp.'s net margin of 39.21%. United Therapeutics Corp.'s return on equity of 19.2% beat Gilead Sciences, Inc.'s return on equity of 41.48%.

United Therapeutics Corp. has a consensus price target of $518.25, signalling upside risk potential of 0.22%. On the other hand Gilead Sciences, Inc. has an analysts' consensus of $132.38 which suggests that it could grow by 6.51%. Given that Gilead Sciences, Inc. has higher upside potential than United Therapeutics Corp., analysts believe Gilead Sciences, Inc. is more attractive than United Therapeutics Corp..

United Therapeutics Corp. has a beta of 0.861, which suggesting that the stock is 13.874% less volatile than S&P 500. In comparison Gilead Sciences, Inc. has a beta of 0.318, suggesting its less volatile than the S&P 500 by 68.175%.

United Therapeutics Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Gilead Sciences, Inc. offers a yield of 2.54% to investors and pays a quarterly dividend of $0.79 per share. United Therapeutics Corp. pays -- of its earnings as a dividend. Gilead Sciences, Inc. pays out 805.23% of its earnings as a dividend.

United Therapeutics Corp. quarterly revenues are $799.5M, which are smaller than Gilead Sciences, Inc. quarterly revenues of $7.8B. United Therapeutics Corp.'s net income of $338.7M is lower than Gilead Sciences, Inc.'s net income of $3.1B. Notably, United Therapeutics Corp.'s price-to-earnings ratio is 19.60x while Gilead Sciences, Inc.'s PE ratio is 19.25x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for United Therapeutics Corp. is 7.97x versus 5.38x for Gilead Sciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Insmed, Inc. has a net margin of 42.36% compared to United Therapeutics Corp.'s net margin of -259.95%. United Therapeutics Corp.'s return on equity of 19.2% beat Insmed, Inc.'s return on equity of -193.23%.

United Therapeutics Corp. has a consensus price target of $518.25, signalling upside risk potential of 0.22%. On the other hand Insmed, Inc. has an analysts' consensus of $214.78 which suggests that it could grow by 22.84%. Given that Insmed, Inc. has higher upside potential than United Therapeutics Corp., analysts believe Insmed, Inc. is more attractive than United Therapeutics Corp..

United Therapeutics Corp. has a beta of 0.861, which suggesting that the stock is 13.874% less volatile than S&P 500. In comparison Insmed, Inc. has a beta of 1.015, suggesting its more volatile than the S&P 500 by 1.49%.

United Therapeutics Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Insmed, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. United Therapeutics Corp. pays -- of its earnings as a dividend. Insmed, Inc. pays out -- of its earnings as a dividend.

United Therapeutics Corp. quarterly revenues are $799.5M, which are larger than Insmed, Inc. quarterly revenues of $142.3M. United Therapeutics Corp.'s net income of $338.7M is higher than Insmed, Inc.'s net income of -$370M. Notably, United Therapeutics Corp.'s price-to-earnings ratio is 19.60x while Insmed, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for United Therapeutics Corp. is 7.97x versus 74.41x for Insmed, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Johnson & Johnson has a net margin of 42.36% compared to United Therapeutics Corp.'s net margin of 21.47%. United Therapeutics Corp.'s return on equity of 19.2% beat Johnson & Johnson's return on equity of 33.27%.

United Therapeutics Corp. has a consensus price target of $518.25, signalling upside risk potential of 0.22%. On the other hand Johnson & Johnson has an analysts' consensus of $209.29 which suggests that it could grow by 1.42%. Given that Johnson & Johnson has higher upside potential than United Therapeutics Corp., analysts believe Johnson & Johnson is more attractive than United Therapeutics Corp..

United Therapeutics Corp. has a beta of 0.861, which suggesting that the stock is 13.874% less volatile than S&P 500. In comparison Johnson & Johnson has a beta of 0.357, suggesting its less volatile than the S&P 500 by 64.296%.

United Therapeutics Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Johnson & Johnson offers a yield of 2.49% to investors and pays a quarterly dividend of $1.30 per share. United Therapeutics Corp. pays -- of its earnings as a dividend. Johnson & Johnson pays out 84.8% of its earnings as a dividend. Johnson & Johnson's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

United Therapeutics Corp. quarterly revenues are $799.5M, which are smaller than Johnson & Johnson quarterly revenues of $24B. United Therapeutics Corp.'s net income of $338.7M is lower than Johnson & Johnson's net income of $5.2B. Notably, United Therapeutics Corp.'s price-to-earnings ratio is 19.60x while Johnson & Johnson's PE ratio is 19.92x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for United Therapeutics Corp. is 7.97x versus 5.43x for Johnson & Johnson. Usually stocks with elevated PS ratios are considered overvalued.